Isofol
Isofol is a publicly listed biotech company developing the drug candidate arfolitixorin to enhance the efficacy of standard treatment for patients with severe forms of cancer. Our goal is s to have a central impact on tomorrow’s cancer treatment, giving more patients the opportunity to respond better to their treatment, improve their prognosis, and gain more time with life. Isofol’s share is listed on Nasdaq Stockholm.
7-day free trial · no credit card
Verified contacts
9
available on Kipplo
LinkedIn employees
11
1 to 10 range
Open roles
—
no listings
Distinct roles
7
indexed titles
Tech stack
1
tools in use
Monthly traffic
8
organic / mo
Sign up free to see all 9 verified contacts at Isofol
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
9 contacts with verified email or phone · masked until revealed.
- MF
Martin Fröström
Interim Accounting Manager · Finance & Accounting
EmailPhone - JB
Jenny Brinkeby
Investor Relation and Marketing Coordinator · Other
EmailPhone - IL
Isabel Löwstedt
Isofol Medical Ab (Publ) · Other
EmailPhone - JO
Jan-Eric Osterlund
Chairman · General Business & Management
EmailPhone - LS
Lisa Skintemo
Isofol Medical Ab (Publ) · Other
EmailPhone - MH
Margareta Hagman
Chief Financial Officer · Finance & Accounting
EmailPhone - RT
Roger Tell
Acting Chief Executive Officer · General Business & Management
EmailPhone
Showing 7 of 9 verified contacts
Top roles at Isofol
7 distinct titles indexed · top 7 shown.
- 3isofol medical ab (publ)
- 1acting chief executive officer
- 1chairman
- 1chairman of the board
- 1chief financial officer
- 1interim accounting manager
- 1investor relation and marketing coordinator
Sign up to unlock all 9 contacts at Isofol
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 9 verified contacts at Isofol
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.